血清肿瘤标志物联合双源 CT 对肺癌的诊断价值比较。
Comparison of serum tumor markers combined with dual-source CT in the diagnosis of lung cancer.
机构信息
Department of Imaging, People's Hospital of Rizhao, Rizhao, China.
Department of Imaging, Lanshan People's Hospital of Rizhao, Rizhao, China.
出版信息
Minerva Med. 2023 Dec;114(6):795-801. doi: 10.23736/S0026-4806.21.07124-X. Epub 2021 Mar 25.
BACKGROUND
The purpose of this study is to explore the clinical value of serum tumor markers combined with dual-source CT scanning in the diagnosis of lung cancer.
METHODS
One hundred-two patients with lung cancer (malignant tumor group), 50 patients with benign lesions (benign control group) and 50 healthy patients (normal control group) were selected as the research objects. The levels of serum carcinoembryonic antigen (CEA), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) and gastrin releasing peptide precursor 31-98 (Pro-GRP31-98) were detected using the electrochemiluminescence and enzyme-linked immunoassay in three groups of people. Simultaneously, Siemens' second-generation dual-source CT (Siemens AG, Munich, Germany) is used to scan the lungs of patients with lung cancer and benign lesions. Retrospective statistical analysis is utilized to explore the clinical value of serum tumor markers combined with dual-source CT examination in the diagnosis of lung cancer.
RESULTS
The levels of serum CEA, CYFRA21-1 and Pro-GRP31-98 in lung cancer patients were significantly higher than those in the benign control group and normal control group, and the difference was statistically significant (P<0.01). There was no statistical difference between the benign control group and the normal control group (P>0.05). The levels of serum CEA, CYFRA21-1, Pro-GRP31-98 had no significant correlation with the age, sex, and tumor site of lung cancer patients (P>0.05). However, the levels of serum CEA, CYFRA21-1, Pro-GRP31-98 have an obvious correlation with tumor size, clinical stage, histological type, combined pleural effusion, recurrence and metastasis after treatment (P<0.05). CT scans of 102 lung cancer patients showed 35 cases of central type, 67 cases of peripheral type, 71 cases with tumor diameter >5cm, 31 cases of ≤5cm and 67 cases of lymph node metastasis. The sensitivities of CEA, CYFRA21-1, Pro-GRP31-98, and dual-source CT in the diagnosis of lung cancer were 64.70%, 60.11%, 56.86% and 77.45%, and the accuracy was 75.00%, 72.37%, 69.74% and 82.89%, respectively. Compared with a single examination, the sensitivity and accuracy of combined examination for the diagnosis of lung cancer were significantly improved, which were 95.10% and 92.76%, respectively.
CONCLUSIONS
Joint examinations can effectively improve the rate of lung cancer diagnosis.
背景
本研究旨在探讨血清肿瘤标志物联合双源 CT 扫描在肺癌诊断中的临床价值。
方法
选取肺癌患者 102 例（恶性肿瘤组）、良性病变患者 50 例（良性对照组）和健康体检者 50 例（正常对照组）为研究对象。采用电化学发光法和酶联免疫吸附法检测三组人群血清癌胚抗原（CEA）、细胞角蛋白 19 片段抗原 21-1（CYFRA21-1）和胃泌素释放肽前体 31-98（Pro-GRP31-98）水平。同时采用西门子第二代双源 CT（德国西门子公司）对肺癌及良性病变患者肺部进行扫描。回顾性统计分析探讨血清肿瘤标志物联合双源 CT 检查在肺癌诊断中的临床价值。
结果
肺癌患者血清 CEA、CYFRA21-1 和 Pro-GRP31-98 水平明显高于良性对照组和正常对照组，差异有统计学意义（P<0.01）。良性对照组与正常对照组比较差异无统计学意义（P>0.05）。肺癌患者血清 CEA、CYFRA21-1、Pro-GRP31-98 水平与年龄、性别、肿瘤部位无明显相关性（P>0.05）。但与肿瘤大小、临床分期、组织学类型、合并胸腔积液、治疗后复发转移明显相关（P<0.05）。102 例肺癌患者 CT 扫描显示中央型 35 例，周围型 67 例，肿瘤直径>5cm 71 例，≤5cm 31 例，淋巴结转移 67 例。CEA、CYFRA21-1、Pro-GRP31-98 及双源 CT 对肺癌的诊断敏感度分别为 64.70%、60.11%、56.86%和 77.45%，特异度分别为 75.00%、72.37%、69.74%和 82.89%。与单项检查比较，联合检查对肺癌的诊断敏感度和准确度均明显提高，分别为 95.10%和 92.76%。
结论
联合检查可有效提高肺癌诊断率。
Zotero 插件